Insmed Incorporated filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on October 29, 2026, reporting net product revenues of $524.4 million and a net loss of $100.3 million for the third quarter.

Key Highlights

  • Product revenues, net: $524,428 thousand for the three months ended September 30, 2026, compared with $142,342 thousand in the same period of 2025.
  • Net loss narrowed: The company reported a net loss of $100,319 thousand for Q3 2026, versus a net loss of $370,021 thousand in Q3 2025.
  • Nine-month revenue: Net product revenues of $1,255,878 thousand for the nine months ended September 30, 2026, up from $342,580 thousand in the comparable 2025 period.
  • Basic and diluted net loss per share: $(0.46) for Q3 2026, compared with $(1.75) for Q3 2025.
  • Cash and marketable securities: Cash and cash equivalents of $396,563 thousand and marketable securities of $750,063 thousand as of September 30, 2026.
  • Shares outstanding: 219,380,309 shares of common stock outstanding as of October 23, 2026.
  • Contingent consideration fair value change: A gain of $139,181 thousand was recorded on the change in fair value of contingent consideration for the nine months ended September 30, 2026, compared with a charge of $181,953 thousand in the nine months ended September 30, 2025.

Insmed's Commercial Revenue Growth and Operating Cost Structure in Q3 2026

According to the filing, Insmed Incorporated, a Virginia-incorporated biopharmaceutical company traded on the Nasdaq Global Select Market under the ticker NASDAQ:INSM, markets products including ARIKAYCE and BRINSUPRI. Net product revenues for Q3 2026 reached $524,428 thousand, representing a significant increase from $142,342 thousand in Q3 2025. For the nine months ended September 30, 2026, cumulative net product revenues totaled $1,255,878 thousand, compared with $342,580 thousand for the same nine-month period in 2025, according to the company's consolidated statements of comprehensive loss.

The filing disclosed that total operating expenses for the three months ended September 30, 2026 were $613,797 thousand, resulting in an operating loss of $89,369 thousand for the quarter. Research and development expense was $269,963 thousand for Q3 2026, while selling, general and administrative expense was $253,029 thousand. Cost of product revenues, excluding amortization of intangible assets, was $78,215 thousand. The company reported investment income of $11,070 thousand and interest expense of $20,410 thousand for the quarter, the filing stated.

As of September 30, 2026, Insmed reported total assets of $2,226,056 thousand and total liabilities of $1,499,842 thousand, leaving total shareholders' equity of $726,214 thousand. The accumulated deficit stood at $5,913,816 thousand at quarter-end, up from $5,636,692 thousand at December 31, 2025. Long-term debt was reported at $544,862 thousand, and the royalty financing agreement carried a long-term balance of $146,231 thousand. During Q3 2026, stock-based compensation expense of $41,220 thousand was recognized, according to the equity statements in the filing.

What Was Disclosed

Insmed Incorporated's Form 10-Q for the quarter ended September 30, 2026 disclosed quarterly net product revenues of $524,428 thousand, a net loss of $100,319 thousand, total assets of $2,226,056 thousand, and 219,380,309 common shares outstanding as of October 23, 2026.